ClinicalTrials.gg
RecruitingNCT07614230SCOPEUpdated May 29, 2026

SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes

A Phase 4 interventional study of Dapagliflozin (DAPA) and Standard Care (Treatment as Usual) in Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease and Atherosclerosis, sponsored by Junjie Yang. Recruiting at 2 sites in China. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Junjie Yang · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2026, registered Apr 2026).
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
71st of 180
144 · median 82
Started
2026
with 6 others
Phase 4
77 of 180
7 open now
Primary completion
2027-06
later than 11 of 18 live
Registered
176th of 180
by date

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 71st largest by planned enrollment, is one of 7 that started in 2026, is one of 77 in phase 4, reaches primary completion later than 11 of the 18 other live ones, and was the 176th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is a multicenter, randomized controlled trial to test whether an SGLT2 inhibitor (dapagliflozin), a type of diabetes medication, can slow down or even reverse the progression of coronary atherosclerosis (plaque buildup in the coronary arteries) in patients with type 2 diabetes. The effect may be mediated by improving the function of perivascular adipose tissue. A total of 144 adults with type 2 diabetes and stable coronary artery disease will be randomly assigned to receive either dapagliflozin plus standard diabetes and cardiovascular care (intervention group) or standard care alone (control group) for 18 months. Serial coronary CT angiography and other assessments will be performed to evaluate changes in coronary plaque volume, CT-derived fractional flow reserve, perivascular fat radiomics score, and various metabolic and inflammatory markers, to determine whether SGLT2 inhibition reduces cardiovascular risk.

Read the detailed description

Randomization and blinding: Eligible participants will be randomly assigned in a 1:1 ratio to either the dapagliflozin group or the standard care control group using a centralized, computer-generated randomization sequence. This is an open-label trial; however, all outcome assessments will be performed by core laboratories blinded to treatment allocation. Imaging analyses for plaque volume, hemodynamic parameters, and perivascular adipose tissue metrics will be conducted by investigators masked to group assignment.

Intervention: Participants in the intervention group receive dapagliflozin 10 mg once daily in addition to their standard diabetes and cardiovascular care. Participants in the control group receive standard glycemic management according to current clinical guidelines, with the exclusion of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors. The total study duration is 18 months.

Study procedures: At baseline, participants will undergo coronary computed tomography angiography (CCTA) using a standardized protocol. Blood samples will be collected for lipid panels and inflammatory markers. Quality of life will be assessed using the Seattle Angina Questionnaire (SAQ-7). Follow-up visits are scheduled at 6, 12, and 18 months. At each visit, adverse events, concomitant medications, and medication adherence will be recorded. The 18-month visit will include a repeat CCTA and blood sampling.

Imaging core laboratory: All CCTA images will be transferred to an independent core laboratory for quantitative analysis. Plaque volume and composition will be assessed using semi-automated software. CT-derived fractional flow reserve (CT-FFR) will be computed using a dedicated algorithm. Wall shear stress (WSS) will be derived from computational fluid dynamics. Perivascular adipose tissue parameters, including fat attenuation index (FAI) and fat volume, will be measured using a validated software tool.

Data and safety monitoring: An independent Data and Safety Monitoring Board (DSMB) will review unblinded safety data every 6 months. The DSMB will monitor for serious adverse events, including volume depletion, genital infections, hypoglycemia, diabetic ketoacidosis, and acute kidney injury. Protocol-defined stopping rules include a significant increase in any of these events in the intervention arm.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Coronary Artery Disease
  • Atherosclerosis

Keywords

  • SGLT2 Inhibitors
  • Dapagliflozin
  • Perivascular Adipose Tissue
  • Coronary Atherosclerosis
  • Type 2 Diabetes
  • Plaque Progression
  • Coronary CT Angiography
  • Cardiovascular Risk
  • PVAT
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 75 years.
  • Confirmed diagnosis of type 2 diabetes mellitus with SCORE2-Diabetes risk score >10%.
  • Stable angina pectoris.
  • Coronary CT angiography (CCTA) demonstrating 50%-90% stenosis in at least one coronary vessel with diameter ≥2.5 mm.
  • CT-derived fractional flow reserve (CT-FFR) >0.8 in the target vessel.
  • Stable standard therapy for diabetes and cardiovascular disease, with no changes in SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors within the past 4 weeks.
  • Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • History of coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI) with stenting, prosthetic valve replacement, or permanent pacemaker implantation.
  • (NYHA) functional class III or IV heart failure. Acute myocardial infarction within the previous 30 days.
  • Known allergy to iodinated contrast media or other to CCTA. Severe arrhythmia or coronary artery calcium (CAC) score >400.
  • Estimated (eGFR) \<45 mL/min/1.73 m². History of serious adverse reactions to SGLT2 inhibitors.
  • Pregnancy, lactation, or planned pregnancy during the study period. Severe liver dysfunction ( class C).
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    SGLT2 Inhibitor Group

    Participants with type 2 diabetes and coronary atherosclerosis receive dapagliflozin 10 mg orally once daily in addition to standard diabetes care for 18 months.

    Drug: Dapagliflozin (DAPA) · Other: Standard Care (Treatment as Usual)

  • Active comparator
    Control Group

    Participants receive standard diabetes care without SGLT2 inhibitors for 18 months.

    Other: Standard Care (Treatment as Usual)

Interventions

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dapagliflozin 10 mg tablet administered orally once daily for 18 months, in addition to standard diabetes and cardiovascular care, to evaluate its effects on coronary atherosclerosis progression mediated by perivascular adipose tissue in patients with type 2 diabetes.

  • OtherStandard Care (Treatment as Usual)

    Standard glycemic and cardiovascular management according to clinical guidelines, excluding SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors, for 18 months.

06

What researchers measure

Primary outcomes

  1. Progression of Coronary Plaque Volume and Proportion from Baseline to the 18-Month Follow-Up

    Progression of total plaque volume (TPV) (mm³)from baseline or appearance of new plaques, assessed by coronary CT angiography (CCTA). Includes changes in plaque components (e.g., necrotic core, fibrous cap, calcification)(mm³).

    Time frame: Baseline to 18 months

Secondary outcomes

  1. Change in the Coronary Perivascular Fat Radiomics Score (FRS) from Baseline to 18 Months

    Change from baseline to the 18-month follow-up in the coronary perivascular fat radiomics score (FRS), measured in "points", where a higher score indicates a higher inflammatory activity state and a stronger correlation with the risk of major adverse cardiovascular events.

    Time frame: Baseline to 18 months

  2. Change in CT-derived fractional flow reserve (CT-FFR) from Baseline to 18 Months

    Change from baseline to the 18-month follow-up in CT-derived fractional flow reserve (CT-FFR), expressed as a pure number between 0 and 1 (no units), where a higher value indicates a lower likelihood of ischemia.

    Time frame: Baseline to 18 months

  3. Change in Fat Attenuation Index (FAI)from Baseline to 18 Months

    Change from baseline to the 18-month follow-up in fat attenuation index (FAI)(HU) .FAI is defined as the mean attenuation value of pericoronary adipose tissue observed on CT scan, ranging from approximately -190 to -30 HU. Higher values indicating increased perivascular adipose tissue inflammation and coronary vulnerability, and lower values suggesting a more stable, anti-inflammatory vascular state.

    Time frame: Baseline to 18 months

  4. Change in the Degree of Coronary Artery Stenosis from Baseline to 18 Months

    Change from baseline to the 18-month follow-up in the degree of coronary artery stenosis, expressed as CAD-RADS category or quantitatively measured percent stenosis. CAD-RADS grades range from 0 to 5, with higher grades indicating greater stenosis severity. Quantitatively measured percent stenosis ranges from 0% to 100%, with higher percentages indicating greater stenosis severity.

    Time frame: Baseline to 18 months

  5. Change in C-reactive protein (CRP) from baseline to 18 months

    Change from baseline to the 18-month follow-up in C-reactive protein (CRP). Reference range: 0-0.8 mg/L; Unit: mg/dL.

    Time frame: Baseline to 18 months

  6. Change in Quality of Life Score as Assessed by the Seattle Angina Questionnaire (SAQ-7) from Baseline to 18 Months

    Change from baseline to the 18-month follow-up in quality of life score measured by the Seattle Angina Questionnaire (SAQ-7). The total score ranges from 0 to 100, with higher scores indicating better quality of life and better angina control.

    Time frame: Baseline to 18 months

  7. Occurrence of Major Adverse Cardiovascular Events (MACE) from Baseline to 18 Months

    Occurrence of major adverse cardiovascular events (MACE), including but not limited to cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, from baseline to the 18-month follow-up.

    Time frame: Baseline to 18 months

  8. Change in Self-Rating Anxiety Scale(SAS) Score from Baseline to 18 Months

    Change from baseline to the 18-month follow-up in the Self-Rating Anxiety Scale (SAS) score. The SAS is a 20-item self-reported scale with 4-point scoring, designed to assess the subjective experience of anxiety in patients. Total scores range from 0 to 60, with higher scores indicating greater anxiety severity. The scores are interpreted as follows: A (0-8): no anxiety disorder B (9-21): occasional anxiety C (22-32): mild anxiety disorder D (33-44): moderate anxiety disorder E (45-60): severe anxiety disorder

    Time frame: Baseline to 18 months

  9. Change in Hamilton Anxiety Scale (HAMA) Score from Baseline to 18 Months

    Change from baseline to the 18-month follow-up in the Hamilton Anxiety Scale (HAMA) score. HAMA is a clinician-rated scale consisting of 14 items, each scored from 0 to 4, where: 0 = asymptomatic 1. = mild symptoms 2. = moderate symptoms (clearly present but does not affect daily life) 3. = severe symptoms (significantly affects daily life) 4. = extremely severe symptoms (unable to function normally) Total scores range from 0 to 56, with higher scores indicating more severe anxiety. The score is interpreted as follows: \<7: no anxiety symptoms 7-13: possible anxiety 14-20: mild anxiety 21-28: marked anxiety 29: severe anxiety

    Time frame: Baseline to 18 months

  10. Change in wall shear stress (WSS) from Baseline to 18 Months

    Change from baseline to the 18-month follow-up in wall shear stress (WSS)(Pa).Both excessively high and abnormally low WSS are pathological: high WSS promotes plaque destabilization and rupture, while low WSS accelerates atherogenesis and plaque growth.

    Time frame: Baseline to 18 months

  11. Change in Pericoronary Adipose Tissue Volume from Baseline to 18 Months

    Change from baseline to the 18-month follow-up in Pericoronary Adipose Tissue Volume (mm³).Larger volume indicates higher inflammatory activity or greater disease burden, whereas smaller volume indicates the opposite.

    Time frame: Baseline to 18 months

  12. Change in lipoprotein(a) (Lp(a)) from baseline to 18 months

    Change from baseline to the 18-month follow-up in lipoprotein(a) (Lp(a)). Reference range: \<30 mg/dL; Unit: mg/dL.

    Time frame: Baseline to 18 months

  13. Change in low-density lipoprotein cholesterol (LDL-C) from baseline to 18 months

    Change from baseline to the 18-month follow-up in low-density lipoprotein cholesterol (LDL-C). Reference range: 0-3.4; Unit: mmol/L.

    Time frame: Baseline to 18 months

  14. Change in high-density lipoprotein cholesterol (HDL-C) from baseline to 18 months

    Change from baseline to the 18-month follow-up in high-density lipoprotein cholesterol (HDL-C). Reference range: 1-1.6 ; Unit: mmol/L.

    Time frame: Baseline to 18 months

  15. Change in triglycerides (TG) from baseline to 18 months

    Change from baseline to the 18-month follow-up in triglycerides (TG). Reference range: 0.4-1.7; Unit: mmol/L.

    Time frame: Baseline to 18 months

  16. Change in total cholesterol (TC) from baseline to 18 months

    Change from baseline to the 18-month follow-up in total cholesterol (TC). Reference range: 3.1-5.7; Unit: mmol/L.

    Time frame: Baseline to 18 months

  17. Change in interleukin-6 (IL-6) from baseline to 18 months

    Change from baseline to the 18-month follow-up in interleukin-6 (IL-6). Reference range: 0-5.9 pg/mL; Unit: pg/mL.

    Time frame: Baseline to 18 months

  18. Change in tumor necrosis factor-alpha (TNF-α) from baseline to 18 months

    Change from baseline to the 18-month follow-up in tumor necrosis factor-alpha (TNF-α). Reference range: \<20; Unit: ng/L.

    Time frame: Baseline to 18 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant privacy and confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 17 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 29, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 31, 2028
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07614230
Lead sponsor
Junjie Yang
Responsible party
Junjie Yang (Associate Professor, Associate Chief Physician, Chinese PLA General Hospital) — Sponsor-investigator
First posted
May 29, 2026
Start date
Jan 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 29, 2026

Study contacts

Junjie Yang, MD
Contact
fearlessyang@126.com
010-55499209

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion